Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioNotebook: PhaseBio closes $40m Series C round led by AstraZeneca, plus five other VC financings

This article was originally published in Scrip

Executive Summary

AstraZeneca led a $40m Series C venture capital round that will fund PhaseBio's Phase IIa clinical trials for drug candidates to treat diabetes and heart failure – two key areas of interest for the UK-based big pharma company.

Advertisement

Related Content

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC028093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel